Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Mineralys Therapeutics, Inc. (MLYS) vs. Competitors

614 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
MLYSMineralys Therapeutics, Inc.$13.66$1.25B-3.13-67.38%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumMLYSUnlock the MLYS top-analyst price target with TipRanks Premium
INVAInnoviva$18.41$1.31B7.25-13.00%Strong BuyUnlock the INVA analyst price target with TipRanks PremiumMLYS vs INVAUnlock the INVA top-analyst price target with TipRanks Premium
RAREUltragenyx Pharmaceutical$16.48$1.76B-3.17-47.15%Moderate BuyUnlock the RARE analyst price target with TipRanks PremiumMLYS vs RAREUnlock the RARE top-analyst price target with TipRanks Premium
ARDXArdelyx$2.99$769.20M-13.31-46.13%Strong BuyUnlock the ARDX analyst price target with TipRanks PremiumMLYS vs ARDXUnlock the ARDX top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$16.13$1.22B-4.13-53.03%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumMLYS vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.02$1.50B-3.64-57.62%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumMLYS vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
MLYSMineralys Therapeutics, Inc.13.66-28.21-67.38%
INVAInnoviva18.41-2.55-12.17%
RAREUltragenyx Pharmaceutical16.48-17.11-50.94%
ARDXArdelyx2.99-2.43-44.83%
GPCRStructure Therapeutics, Inc. Sponsored ADR16.13-18.19-53.00%
KLRAKailera Therapeutics, Inc.11.02-14.98-57.62%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts